SG11201508405QA - 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors - Google Patents

2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Info

Publication number
SG11201508405QA
SG11201508405QA SG11201508405QA SG11201508405QA SG11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA
Authority
SG
Singapore
Prior art keywords
aminopyrido
wee
pyrimidin
inhibitors
derivatives
Prior art date
Application number
SG11201508405QA
Inventor
Colin Roderick O'dowd
James Samuel Shane Rountree
Frank Burkamp
Andrew John Wilkinson
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of SG11201508405QA publication Critical patent/SG11201508405QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11201508405QA 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors SG11201508405QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1306610.5A GB201306610D0 (en) 2013-04-11 2013-04-11 Pharmaceutical compounds
PCT/GB2014/051136 WO2014167347A1 (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201508405QA true SG11201508405QA (en) 2015-11-27

Family

ID=48537110

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508405QA SG11201508405QA (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Country Status (16)

Country Link
US (1) US9714244B2 (en)
EP (1) EP2984090B1 (en)
JP (1) JP6412920B2 (en)
KR (1) KR102250668B1 (en)
CN (1) CN105209463B (en)
AU (1) AU2014252828B2 (en)
BR (1) BR112015026023A2 (en)
CA (1) CA2909365C (en)
GB (1) GB201306610D0 (en)
HK (1) HK1219474A1 (en)
IL (1) IL242000B (en)
MX (1) MX362215B (en)
RU (1) RU2656342C2 (en)
SG (1) SG11201508405QA (en)
WO (1) WO2014167347A1 (en)
ZA (1) ZA201507874B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864142A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
KR101845931B1 (en) 2015-06-18 2018-04-05 한국화학연구원 Heteroaryl derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases
WO2016204429A1 (en) * 2015-06-18 2016-12-22 한국화학연구원 Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
CN107459519A (en) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 Annelated pyrimidines piperidines ring derivatives and its preparation method and application
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN110198943B (en) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one derivatives as Wee1 inhibitors
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
WO2019014513A1 (en) * 2017-07-13 2019-01-17 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc Heterocyclic compounds and uses thereof
AU2018361010B2 (en) 2017-11-01 2023-01-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
JP2022505756A (en) 2018-10-26 2022-01-14 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド Pyramide pyrazolone derivatives and their use as Wee1 inhibitors
KR20200100429A (en) * 2019-02-18 2020-08-26 한국과학기술연구원 NOVEL PYRIDO[3,4-d]PYRIMIDIN-8-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS AND COMPOSITIONS FOR PREVENTING, IMPROVING OR TREATING CANCER CONTAINING THE SAME
EP3943496A4 (en) 2019-03-22 2022-05-18 Shouyao Holdings (Beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
AU2020271837A1 (en) 2019-04-09 2021-11-18 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP2022530812A (en) 2019-04-30 2022-07-01 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド Crystal form of Wee1 inhibitor compound and its applications
EP4169919A1 (en) 2020-06-17 2023-04-26 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Pyrazolo[3,4-d]pyrimidine-3-ketone derivative as wee-1 inhibitor
KR20240004539A (en) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Condensed ring compounds as WEE-1 inhibitors, preparation methods therefor, and uses thereof
KR20240044409A (en) * 2021-06-04 2024-04-04 아프레아 테라퓨틱스, 인크. Pyridopyrimidine derivatives useful as WEE1 kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي 2-Amino-7,8-Dihidro-6H-Pyrido(4,3-D)Pyrimidin-5-ones
PE20080695A1 (en) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd DIHYDROPIRAZOLOPYRIMIDINONE DERIVATIVES AS KINASE WEEL INHIBITORS
ES2432414T3 (en) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Chemical compounds
CN102227220A (en) * 2008-11-28 2011-10-26 诺瓦提斯公司 Hsp90 inhibitors for therapeutic treatment
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
US8507505B2 (en) * 2008-12-12 2013-08-13 Msd K.K. Dihydropyrazolopyrimidinone derivative
AR075180A1 (en) * 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
MX2014000621A (en) * 2011-07-15 2014-11-10 Abbvie Inc Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases.
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
CA2864142A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Also Published As

Publication number Publication date
MX2015014234A (en) 2016-06-16
ZA201507874B (en) 2017-09-27
IL242000B (en) 2021-03-25
JP6412920B2 (en) 2018-10-24
CA2909365A1 (en) 2014-10-16
EP2984090A1 (en) 2016-02-17
KR20150143668A (en) 2015-12-23
EP2984090B1 (en) 2017-05-31
JP2016516763A (en) 2016-06-09
BR112015026023A2 (en) 2017-07-25
HK1219474A1 (en) 2017-04-07
CN105209463B (en) 2017-10-13
KR102250668B1 (en) 2021-05-10
CN105209463A (en) 2015-12-30
AU2014252828A1 (en) 2015-11-05
RU2015148189A (en) 2017-05-23
RU2656342C2 (en) 2018-06-05
AU2014252828B2 (en) 2018-07-05
GB201306610D0 (en) 2013-05-29
NZ713114A (en) 2021-01-29
CA2909365C (en) 2021-11-09
US9714244B2 (en) 2017-07-25
MX362215B (en) 2019-01-09
WO2014167347A1 (en) 2014-10-16
US20160060258A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
CU20160077A7 (en) PIRROLO [2,3-D] PYRIMIDINYL, PIRROLO [2,3-B] PYRAZINYL AND PIRROLO [2,3-D] PIRIDINYL ACRYLIC
IL241184A0 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
HK1217708A1 (en) New triptolide derivatives and preparation method and use thereof
IL243092B (en) Novel triazolo[4,5-d]pyrimidine derivatives
HRP20190013T1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
IL243525A0 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
HK1216749A1 (en) 1,7-naphthyridine derivatives 17-
HUE038261T2 (en) New azabenzimidazole derivatives
IL241359A0 (en) Substituted indol-5-ol derivatives, compositions comprising same and uses thereof
EP3030239A4 (en) Urea derivatives and uses thereof
SI3027613T1 (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
IL240177A (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
SG11201601135QA (en) 3-substituted cyclopentylamine derivatives
EP3019165A4 (en) Dehydroleucodine derivatives and uses thereof
AU2013902560A0 (en) Heterocyclic compounds and their use